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ABSTRACT
Background Anemia is associated with poor clinical outcome after ischemic and hemorrhagic 
stroke. We examined the association between anemia and outcome in patients with cerebral 
venous thrombosis (CVT). 
Methods Consecutive adult patients with CVT were included from seven centers. Anemia at 
admission was scored according to World Health Organization definitions. Poor clinical outcome 
was defined as a modified Rankin Scale (mRS) score 3-6 at last follow-up. A multiple imputation 
procedure was applied for handling missing data in the multivariable analysis. Using binary 
logistic regression analysis, we adjusted for age, sex, cancer, and center of recruitment (model 1). 
In a secondary analysis we additionally adjusted for coma, intracerebral hemorrhage, non-
hemorrhagic lesion, and deep venous system thrombosis (model 2). In a sensitivity analysis we 
excluded patients with cancer.
Results Data of 952 patients with CVT were included, 22% of whom had anemia at admission. 
Patients with anemia more often had a history of cancer (17% vs. 7%, p<0.001) than patients 
without anemia. Poor clinical outcome (21% vs. 11%, p<0.001) and mortality (11% vs. 6%, 
p=0.07) were more common among patients with anemia. After adjustment, anemia at admission 
increased the risk of poor outcome (adjusted odds ratio [aOR]: 2.4, 95% confidence interval [CI] 
1.5-3.7, model 1). Model 2 revealed comparable results (aOR 1.9, 95% CI 1.2-3.2), as did the 
sensitivity analysis excluding patients with cancer (aOR 2.3, 95% CI 1.3-3.8, model 1).
Conclusion The risk of poor clinical outcome is doubled in CVT patients presenting with anemia 
at admission. 
Introduction
Cerebral venous thrombosis (CVT) is a rare thrombotic disorder and an infrequent cause of stroke 
that mainly affects young adults and children [1]. Approximately 9 to 27% of patients with CVT 
have anemia at presentation, and the presence of anemia has been shown to increase the risk of 
CVT [2, 3]. In adults, the most common cause of microcytic anemia is iron deficiency. The latter 
has been associated with thrombocytosis and increased concentrations of factor VIII, which are 
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In patients with ischemic and hemorrhagic stroke, the presence of anemia had been found to be 
associated with poor clinical outcome [6, 7]. One proposed mechanism is that low hemoglobin 
levels impair oxygen delivery to the damaged brain, and induce an inflammatory response [8]. 
Data from a recent single center study suggest that an association between anemia and poor 
clinical outcome also exists in CVT, but this study had a limited sample size [9]. The aim of our 
study was to assess the association between anemia and poor clinical outcome in CVT, using data 
from a large international CVT consortium. 
Methods 
Study design and patient inclusion
Data were derived from seven hospital-based CVT registries from the international CVT 
consortium: Amsterdam UMC (the Netherlands), Helsinki University Hospital (Finland), 
Sahlgrenska University Hospital (Sweden), Inselspital Bern University Hospital (Switzerland), 
National Institute Manuel Velasco Suarez (Mexico), Hamadan University of Medical Science 
(Iran), and Hospital Dr. Calderón Guardia (Costa Rica). Detailed information on consecutive 
patients with CVT has been collected prospectively since January 2006 (Amsterdam), January 
2010 (Helsinki), January 2000 (Bern), January 2008 (Mexico-City), April 2012 (Hamadan), and 
May 2015 (San José). Data were collected retrospectively from January 1987 until January 2010 
(Helsinki), and January 1997 (Gothenburg). Since only observational data were collected in each 
of the CVT registries, written informed consent was not required under applicable national laws. 
All data that we collected were part of routine patient care. According to local regulations, in this 
specific situation, no formal ethical approval is required.
We included all adult patients diagnosed with CVT until 1 March 2018. To increase the 
generalizability of the results, no exclusion criteria were applied. Data were recorded using a 
standardized case record form. Diagnosis of CVT had to be confirmed with CT-venography, MRI 
with MR-venography, catheter angiography, or autopsy [10]. Poor clinical outcome was defined as 
a score of 3 to 6 on the modified Rankin Scale (mRS), assessed at the last available follow-up 
contact. Mortality and mRS 0-1 were also analyzed separately.
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Hemoglobin concentration was measured in venous blood samples as a part of routine medical 
care, and the first hemoglobin measurement that was performed at arrival at the hospital was used 
for analysis, with a maximum of 48 hours after admission. We used the World Health 
Organization definitions for anemia: men <130 g/L, non-pregnant women hemoglobin <120 g/L, 
and pregnant women <110 g/L [11]. Patients with hyperhemoglobinemia (men >175 g/L, women 
>155 g/L) were categorized in the “no anemia” group. Anemia subgroups were defined as: mild 
anemia (men: 110-129 g/L, non-pregnant women: 110-119 g/L, pregnant women: 100-109 g/L), 
and moderate to severe anemia (men/non-pregnant women: <110 g/L, pregnant women: <100 
g/L). Anemia was further categorized as microcytic (mean corpuscular volume [MCV] <80 fL), 
normocytic (MCV 80-100 fL), or macrocytic (MCV >100 fL).
Statistical analysis
We compared patients with anemia to those without anemia. Differences between groups were 
analyzed with a chi-square test, Fisher’s exact test, or Mann-Whitney U-test, as appropriate. A 
multiple imputation procedure was used to account for handling missing data in the multivariable 
analysis. The following variables were imputed: hemoglobin concentration, MCV, thrombocytes, 
baseline coma, intracerebral hemorrhage, non-hemorrhagic lesion (cerebral edema/infarction), 
deep venous system thrombosis, and mRS at follow-up. The proportion of patients with missing 
data prior to imputation is reported and for baseline characteristics only non-imputed data are 
shown. In total, 5 data sets were imputed, and results were pooled according to Rubin’s rules. We 
applied multivariable binary logistic regression analysis to study the association between 
admission anemia and clinical outcome (mRS 0-2 vs. 3-6, mRS 0-1 vs. 2-6, and mortality), using 
two different models. In the first model we adjusted for potential confounders that were 
considered to have a causal relation both with anemia and outcome: age, sex, and cancer, and for 
center of recruitment. In the second model, we used all variables of model 1 and additionally 
adjusted for known predictors of poor outcome in CVT: coma, intracerebral hemorrhage, non-
hemorrhagic lesion, and deep venous system thrombosis [3]. We performed a sensitivity analysis 
excluding patients with cancer. We also used multivariable ordinal logistic regression analysis to 
calculate the adjusted common odds ratio (acOR) for a shift in the direction of poor clinical 
outcome on the mRS in the presence of anemia. In a separate analysis, we analyzed hemoglobin as 
a continuous variable, and in subgroup analyses we stratified for mild versus moderate or severe 
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or postpartum, women using oral contraceptives, and in CVT patients with cancer. All data were 
analyzed with SPSS statistical software, version 24.
Results 
There were 952 patients diagnosed with CVT within the study period (n=225 Amsterdam cohort, 
n=246 Helsinki cohort, n=127 Gothenburg cohort, n=182 Bern cohort, n=77 Mexico-City cohort, 
n=70 Hamadan cohort, n=25 San-José cohort). Numbers of patients with imputed data were as 
follows: hemoglobin n=78, MCV n=238, thrombocytes n=88, baseline coma n=4, intracerebral 
hemorrhage n=6, non-hemorrhagic lesion (n=5), deep venous system thrombosis n=1, mRS at last 
follow up n=2. After exclusion of the 78 patients with missing hemoglobin, 874 patients were 
included in the baseline comparison (Table 1). There were no significant differences in the 
baseline characteristics between the included and excluded patients (data not shown).
Of the 874 included patients, 196 (22%) had anemia (median hemoglobin 109 g/L, interquartile 
range [IQR] 94-117). Of the patients with anemia, 102 patients (52%) had mild anemia and 94 
(48%) had moderate to severe anemia. There were 56 patients (29%) with microcytic anemia, 98 
patients (50%) with normocytic anemia, and 2 patients (1%) with macrocytic anemia. 
Hyperhemoglobinemia was present in 42 patients. Causes of anemia are reported in Table 2. 
Hemoglobin values normalized in 10 patients during admission, one of whom received a blood 
transfusion. In total, 26/196 patients (13%) received a blood transfusion during admission. Patients 
with admission anemia were younger (median age 37 vs. 42 years, p=0.02) more often had a 
history of cancer (17% vs. 7%, p<0.001), more often presented with coma (11% vs. 5%, p=0.001), 
and more often had non-hemorrhagic parenchymal lesions (44% vs. 30%, p<0.001, Table 1). 
Median duration of follow-up was 6 months in patients with anemia (IQR 5-13 months) and 7 
months in patients without anemia (IQR 6-12 month, p=0.276). Poor clinical outcome was more 
common in patients with anemia (mRS 3-6: 21% vs. 11 %, p<0.001). Mortality was also increased 
in anemic patients (11% vs. 6%; p=0.07). After adjustment, anemia at baseline was associated 
with an increased risk of poor clinical outcome (adjusted odds ratio [aOR] mRS 3-6: 2.4, 95% CI 
1.5-3.7, model 1; Table 3). There was also a trend towards an increased risk of mortality (aOR 1.7, 
95%CI 0.9-3.1) and a lower chance of mRS 0-1 (aOR 0.7, 95% CI 0.5-1.0). Additional adjustment 
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revealed similar results (aOR 1.9, 95% CI 1.2-3.2; model 2). The results of the sensitivity analysis 
excluding patients with cancer were comparable to the main analysis (aOR 2.3, 95% CI 1.3-3.8).
The full distribution of the mRS is shown in figure 1. Ordinal logistic regression analysis 
demonstrated a shift in the distribution of the mRS towards poor clinical outcome in the presence 
of anemia (adjusted common odds ratio 1.4, 95% CI 1.0-1.9). When hemoglobin was analyzed as 
a continuous variable, there was an inverse association between hemoglobin and poor clinical 
outcome (aOR for mRS 3-6 per 10 g/L increase in hemoglobin concentration: 0.83, 95% CI 0.72-
0.95). 
Stratification by severity of anemia revealed that the risk of poor clinical outcome was increased 
in both patients with mild and patients with moderate to severe anemia (aOR mild anemia 1.8, 
95% CI 1.0-3.3; aOR moderate to severe anemia 3.1, 95% CI 1.8-5.5; Table 4). Subgroup analyses 
demonstrated an increased risk of poor clinical outcome in both male and female anemic patients 
with CVT (Table 3). 
Discussion 
In this large international observational study, we found that anemia was an independent predictor 
of poor clinical outcome in patients with CVT. The risk of death or dependency (mRS 3-6) was 
approximately doubled in patients with anemia. Furthermore, we observed a meaningful sign of 
exposure-response relationship.
The strength of the association between anemia and poor clinical outcome in our CVT cohort is 
similar to results of studies in arterial ischemic stroke and hemorrhagic stroke [6]. Our study may 
have been underpowered to detect an association with mortality. Studies on ischemic stroke had 
data of thousands of patients available and the rate of mortality is also higher is this condition. We 
identified only one other study that examined the association between outcome and anemia in 
CVT [9]. This study found a more pronounced association between anemia and both poor clinical 
outcome (aOR 3.6) and mortality (aOR 5.5) than the current study. However, this was a 
retrospective, single center study and thus the estimate of the strength of the association may be 
less accurate. Interestingly, in this study, mortality was twice as high compared to our study (14% 
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CVT [12]. There were differences in baseline characteristics that may partly explain the difference 
in mortality. Most notably, the proportion of anemic patients that was comatose at admission was 
substantially higher (25 vs. 11%) and coma is one of the strongest predictors of poor outcome in 
CVT [3]. Also, a very large proportion of patients in the study by Liu et al. received endovascular 
treatment, which may also indicate a generally more severe clinical condition of their population.
There are several hypotheses that may explain the association between anemia and poor clinical 
outcome in patients with arterial ischemic stroke, and some of these may also apply to CVT. 
Anemia is thought to induce a hyperdynamic circulation that triggers an inflammatory response, 
consequently leading to increased thrombus formation [8]. In the presence of a parenchymal 
lesion, lower oxygen carrying capacity of the blood in anemic patients may induce increased 
hypoxia in the affected tissue [6, 13, 14]. Further, there is evidence from experimental studies that 
hypoxic anemia can lead to secondary ischemic brain tissue due to upregulation of inflammatory 
mediators [15, 16]. The higher rate of baseline parenchymal lesions in anemic patients provides 
support to this hypothesis.
Despite the abovementioned hypotheses, the observation of an association obviously does not 
prove the presence of a causal relationship between anemia and outcome in CVT. However, if 
such a causal relationship would exist, treatment to raise hemoglobin levels in anemic patients, 
might improve outcome. The efficacy of red blood cell transfusion has been evaluated in one 
observational study in anemic patients with intracerebral hemorrhage. The results were promising, 
but until these results have been confirmed in a randomized trial, a more liberal transfusion 
practice outside the current transfusion guidelines in anemic CVT patients is not justified [17, 18].
Strengths of our study are the large sample size and the multi-center design with data from both 
middle and high-income countries. Our study also has several limitations. First, we had to exclude 
78 cases (8%) for baseline analysis because of missing baseline hemoglobin. In order to minimize 
the risk of bias, we used a multiple imputation procedure to account for the missing data in 
multivariable analysis. Second, although data from consecutive cases were included, part of our 
data was collected retrospectively. Third, there was no pre-defined follow-up time point. Centers 
followed local protocols regarding follow-up intervals and last available mRS was used in 
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without anemia, and we adjusted the analysis for center of recruitment, which negates this 
potential bias. Fourth, analysis by red blood cell morphology to evaluate anemia was not possible, 
because these ancillary investigations were not routinely performed. Finally, our study was 
underpowered to reliably investigate the risk of poor clinical outcome in specific CVT subgroups.
In conclusion, our study shows that admission anemia occurs in about one fifth of patients with 
CVT and that anemia is an independent predictor of poor clinical outcome in these patients. 
Whether a causal relationship underlies this association and whether increasing hemoglobin levels 
improves clinical outcome require further study. 
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Table 1 Baseline characteristics and treatment
Anemia No anemia P-value
N=196 N=678
Demographics
Women, n, % 144/196 (74%) 464/678 (68%) 0.17
Median age [IQR] 38 (27-49) 42 (29-54) 0.02
Onset to diagnosis (median [IQR] in days) 4 (2-9) 5 (2-10) 0.25
Risk factors: n/N [%]
Oral contraceptive usea 57/142 (40%) 236/461 (51%) 0.02
Pregnancy, puerperiuma 25/144 (17%) 46/464 (10%) 0.02
Previous thrombosis 15/196 (8%) 63/671 (9%) 0.46
Cancer 33/196 (17%) 50/677 (7%) <0.001
Characteristics at presentation
Headache 158/192 (82%) 587/672 (87%) 0.07
Focal neurological deficits 126/193 (65%) 391/676 (58%) 0.06
Seizure(s) 74/195 (38%) 202/673 (30%) 0.04
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Laboratory findingsb
Glucose (mmol/l) 6.3 ± 1.7 6.5 ± 2.4 0.57
Mean corpuscular volume (fl) 81 ± 12 89 ± 5 <0.001
Thrombocyte count (10^9/l) 283 ± 117 260 ± 83 0.28
Radiological characteristics
Any parenchymal lesion 118/194 (61%) 348/677 (51%) 0.02
Non-hemorrhagic lesion 85/194 (44%) 205/677 (30%) <0.001
Intracranial hemorrhage 69/193 (36%) 213/677 (32%) 0.26
Superior sagittal sinus thrombosis 95/195 (49%) 361/678 (53%) 0.27
Deep venous system thrombosis 20/195 (10%) 72/678 (11%) 0.88
Thrombosis in multiple veins or sinus (≥3) 32/195 (16%) 165/178 (24%) 0.02
Treatment
Anticoagulation 186/196 (95%) 654/677 (97%) 0.27
Endovascular treatment 15/196 (8%) 37/678 (6%) 0.25
Decompressive hemicraniectomy 17/196 (9%) 33/678 (5%) 0.04
IQR interquartile range, GCS Glasgow Coma Scale
a Percentage of women
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Table 2 Cause of anemia
Suspected cause Frequency n/N (%)





Inflammatory bowel disease 
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Table 3 Association between anemia and clinical outcome







mRS 3-6 47/219 (21%) 82/733 (11%) 2.2 (1.4-3.4) 2.4 (1.5-3.7) 1.9 (1.2-3.2)
Mortality 23/219 (11%) 44/733 (6%) 1.9 (1.0-3.5) 1.7 (0.9-3.1) 1.4 (0.7-2.9)
mRS 0-1 124/219 (57%) 476/733 (65%) 0.7 (0.5-1.0) 0.7 (0.5-1.0) 0.8 (0.6-1.2)
OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale
Binary logistic regression analysis is based on the pooled estimate after multiple 
imputation to account for missing variables.
aAdjusted for age, sex, cancer, and center of recruitment
bAdjusted for sex, age, cancer, coma, intracerebral hemorrhage, non-hemorrhagic 
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Table 4 Stratification by severity of anemia







Functional status mRS, 0-2 mRS, 3-6
  Mild 95/823 (12%) 21/129 (16%) 1.8 (1.0-3.2) 1.8 (1.0-3.3) 1.5 (0.8-2.8)
  Moderate to 
severe
77/823 (9%) 27/129 (21%) 2.6 (1.5-4.7) 3.1 (1.8-5.5) 2.4 (1.2-4.7)
Mortality Alive Dead
  Mild 106/885 (12%) 10/67 (15%) 1.6 (0.7-3.6) 1.4 (0.6-3.1) 1.3 (0.5-3.1)
  Moderate to 
severe
91/885 (10%) 13/67 (19%) 2.1 (1.0-4.4) 2.2 (1.0-4.7) 1.6 (0.6-4.0)
OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale
Binary logistic regression analysis based on the pooled estimate after multiple 
imputation to account for missing variables.
aAdjusted for age, sex, cancer, and center of recruitment
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lesion, thrombosis deep venous system, and center of recruitment.









Men 15/58 (26%) 27/236 (11%) 2.5 (1.2-5.0) 2.7 (1.2-5.7)a
Women 32/158 (20%) 54/498 (11%) 2.1 (1.2-3.6) 2.3 (1.3-4.1)a
   Pregnancy/puerperium 6/26 (23%) 4/49 (8%) 2.6 (0.7-9.6) 2.5 (0.6-10.3)a
   Oral contraceptive use 11/65 (17%) 12/253 (5%) 4.2 (1.6-10.8) 2.6 (0.9-7.8)a
Cancer 14/36 (39%) 15/54 (28%) 1.8 (0.6-5.0) 2.8 (0.9-9.4)b
OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale
Binary logistic regression analysis based on the pooled estimate after multiple imputation to 
account for missing variables.
aAdjusted for age, cancer, and center of recruitment
bAdjusted for age, sex, and center of recruitment
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